An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study
Condition: Solid Tumor
MeSH terms: Neoplasms
Intervention: Onartuzumab; Bevacizumab; Erlotinib
Intervention description: Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).; All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.; All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
Intervention MeSH terms: Bevacizumab; Erlotinib Hydrochloride
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Intervention model: Single Group Assignment
Masking: None (Open Label)
Enrollment: 12.0
Sex: All
Minimum age: 18 Years
Healthy volunteers: No

Summary:

      This extension study will provide continued onartuzumab and/or parent trial (P-trial)
      designated control treatments to participants with cancer who were previously enrolled in a
      company-sponsored onartuzumab P-trial and who derived benefit, as assessed by the responsible
      investigator, from the therapy administered in the P-trial. The study will also collect
      safety data with regard to administration of continued onartuzumab therapy.
    

Eligibility criteria:

        Inclusion Criteria:

          -  Enrolled and receiving either control treatment or onartuzumab-based study treatment
             in an eligible P-trial

          -  Has not met the treatment discontinuation criteria specified in their P-trial protocol
             at the time of enrollment into the extension trial (E-trial)

          -  Ability to begin treatment in the extension (rollover) protocol within 15 days
             following the last day of the study in the antecedent protocol

          -  For women who are not postmenopausal (greater than or equal to [>/=] 12 months of
             non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or
             uterus): agreement to remain abstinent or use single or combined non-hormonal
             contraceptive methods that result in a failure rate of less than (<) 1 percent (%) per
             year during the treatment period and for at least 180 days after the last dose of
             study drug

          -  For men: agreement to remain abstinent or use a condom plus an additional
             contraceptive method that together result in a failure rate of < 1% per year during
             the treatment period and for at least 180 days after the last dose of study drug and
             agreement to refrain from donating sperm during this same period

        Exclusion Criteria:

          -  Pregnancy or lactation or intention to become pregnant during the study (serum
             pregnancy test required before enrollment)

          -  Any non-protocol anti-cancer therapy started between discontinuation from treatment in
             P-trial and start of enrollment in E-trial.